Technology Transfer All the Way.

File:Rasagiline-3D-balls-B.png

A flagship example of T3 Technology Transfer: Rasagiline – a discovery by Prof. Moussa Youdim now marketed as a drug for Parkinsons disease Azilect(TM) by Teva Pharmaceuticals, also demonstrates the powerful Technion process of technology transfer – from the lab. to the marketplace. Image: Wikicommons.

The company Mazor Robotics won FDA approval to apply its robotic surgical system to neurosurgery in July 2012. In the same month, the flagship company Corindus won FDA approval for its CorPath 200 System to be used in performing percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD).Recent global headlines have evidenced the ongoing miracle of Israel’s ability to translate new discoveries into patented innovations that become applicable on world markets. In the past two months, two flagship companies created through the dynamic activities of the T3 – the Technion office of Technology Transfer, passed the key milestone and significant hurdle in the process of effective technology transfer, with the reception of approval from the US Food and Drug Administration (FDA).

The mission of T3 – the technology transfer arm of the Technion, is to transform scientific discoveries and innovative technologies into real-life, applied solutions for the advancement of humanity, the State of Israel, and the Technion. By creating optimal alliances between scientists, industry and investors, T3 facilitates the smooth transfer of technologies to the commercial sector. This is accomplished through the licensing of intellectual property and the establishment of start-up companies. Occasionally, T3 also plays an active role as an entrepreneur by building teams, preparing business plans and providing the capital necessary to bring the technologies developed by Technion researchers to maturity.

The Technion – Israel Institute of Technology is Israel’s first university and home to three Nobel Laureates. The Technion is credited worldwide for its ability to generate start-ups, its remarkable ability to innovate and its powerful connections to industry. Known as “Israel’s MIT,” the Technion has made a significant impact across the range of applied science and technology including electronics, information technology, water management, nanotechnology, life sciences & chemistry, clean-tech, materials engineering and aerospace engineering.

During the past years, T3 has enjoyed a robust and marked increase both in the number of patent families originating from Technion research as well as in the number of commercialization successes. With 80-100 new patent filings every year, over 400 granted patents and over 900 pending patents, Technion now has approximately 400 patent families available for commercialization.

 

 oraclead

The future: knife-free non-invasive cancer surgery.

Insightec – voted a top innovator by TIME Magazine for its revolutionary ultrasound system for non-invasive surgery, is a powerhouse of Technion graduates. Here, Yoav Medan, who has taught at the department of electrical engineering at the Technion and who has graduated from there in aeronautical engineering, discusses how this patented Israeli system could soon be saving lives across the planet.

Imagine having a surgery with no knives involved. At TEDMED, surgeon Yoav Medan shares a technique that uses MRI to find trouble spots and focused ultrasound to treat such issues as brain lesions, uterine fibroids and several kinds of cancerous growths.

‘TIME’ honors InSightec’s Focused Ultrasound

By Viva Sarah Press
December 06, 2011
TIME magazine recently called InSightec’s MR Guided Focused Ultrasound (MRgFUS) one of the 50 best inventions of the year.

“Magnetic-resonance-imaging (MRI) and ultrasound technologies are each remarkable in their own right, but combine them and you get something life-changing,” the magazine wrote about InSightec’s technique.

Read full story at Israel 21C

Yoav Medan

Vice President and Chief Systems Architect, Insightec

Yoav Medan, Vice President and Chief Systems Architect, is responsible for developing new platforms for the Magnetic Resonance guided Focused Ultrasound technology.
Prior to joining InSightec in 1999, Dr. Medan spent 17 years in various senior research and management positions at the IBM Research Division and was elected to the IBM Academy of Technology.
In addition to technical and managerial experience, Dr. Medan has academic experience as well, teaching at the EE department at the Technion, Israel Institute of Technology, in addition to serving as a lecturer for Avionic Systems at the Aeronautical Engineering faculty. He is also a Senior Member of the Institute of Electrical and Electronics Engineers.
Dr. Medan has widely published and holds nine IBM as well as several other patents. He was awarded the IBM Outstanding Technical Achievement Award, the 3rd Invention Achievement Award and the Outstanding Research Division Award.
Dr. Medan received his D.Sc. and B.Sc.(Summa Cum Laude) in Aeronautical Engineering from the Technion, Israel Institute of Technology, and a M.B.A diploma from Bradford University, UK.

The focused ultrasound beam can be seen during the treatment to ensure taht the ultrasound travels through a safe pathway to the focus. This ensures that the correct region is targeted.  Sonication parameters can be adjusted to optimize the treatment and are monitored by the physician during the treatment.